V. M. Kovalenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. M. Kovalenko has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Elena G Nesukay
National Scientific Center «M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine» of NAMS of Ukraine, Kyiv, Ukraine
7 shared publications - S. V. Cherniuk
ДУ «Національний науковий центр “Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска” НАМН України», Київ
7 shared publications - R. M. Kirichenko
ДУ «Національний науковий центр “Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска” НАМН України», Київ
6 shared publications - A. B. Slyvna
ДУ «Національний науковий центр “Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска” НАМН України», Київ
4 shared publications - Nataliia Grygorieva
State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
4 shared publications - Ninel V. Dedukh
D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
4 shared publications
Latest Publications
- Open Access
- 26 February 2025
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 32 (1) , 29-35
Ефективність азатіоприну в лікуванні хворих із тяжким перебігом міокардиту: досвід одного центру
The aim – to evaluate the efficacy of combined immunosuppressive therapy with azathioprine and methylprednisolone in patients with severe myocarditis who did not improve left ventricular (LV) systolic function after 6 months of glucocorticoid (GC) therapy.Materials and methods. The study included 26 patients with chronic myocarditis, disease duration of more than 6 months and lack of efficacy of previous GC administration: functional class (FC) of HF remained at level II or higher, LV ejection fraction (EF) remained <40% at the time of inclusion in the study. All patients on the background of HF therapy according to modern standards were prescribed combined immunosuppressive therapy: azathioprine at a dose of 1 mg/kg of body weight for 6 months in combination with methylprednisolone at a dose of 0.25 mg/kg per day for 3 months with a gradual dose reduction of 1 mg per week until complete drug withdrawal 6 months after the start of treatment. Determination of the content of immunological biomarkers in the blood, cardiac magnetic resonance imaging (CMR) with intravenous contrast, transthoracic echocardiography and a 6-minute walk test were performed before the appointment of combined immunosuppressive therapy and after 6 months of treatment.Results. Before the appointment of combined immunosuppressive therapy, the average number of LV segments in which signs of inflammation were determined in the form of early contrast and/or T2 signal intensity enhancement was 7.25±0.36 segments, and the number of segments with fibrotic myocardial damage was 5.81±0.32 on average. After 6 months, inflammatory changes were detected only in 2.20±0.17 LV segments, while the volume of fibrotic LV damage did not significantly change compared to the initial examination. When analyzing echocardiography data after 6 months of observation, a significant decrease in the LV end-diastolic volume index by 15.6% (p<0.05) and an increase in LV EF by 16.7% (p<0.05) were found. Also, after 6 months of observation, a significant decrease in the content of systemic inflammation markers was detected: the level of ferritin decreased by 41.5% (p<0.01), C-reactive protein – by 34.2% (p<0.01), the content of interleukin-6 and tumor necrosis factor α decreased by 93.8% and 33.3%, respectively (p<0.01), and the content of troponin I decreased 3 times compared to the baseline level before the appointment of azathioprine. According to the results of the 6-minute test, before the appointment of azathioprine, patients with FC III HF predominated, only a third had FC II, and 20% – FC IV. After 6 months of treatment, more than half of the studied patients had FC II HF, every fourth – FC I, and FC IV was not diagnosed in any patient.Conclusions. In patients with severe myocarditis, combined immunosuppressive therapy with azathioprine and glucocorticoids for 6 months was accompanied by a decrease in dilatation and improving the contractility of the left ventricle, improving the functional class of heart failure, reducing the number of myocardial segments affected by inflammatory changes as well as reducing the content of systemic inflammation markers.
- 26 February 2025
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 32 (1) , 29-35
Open AccessЕфективність азатіоприну в лікуванні хворих із тяжким перебігом міокардиту: досвід одного центру
The aim – to evaluate the efficacy of combined immunosuppressive therapy with azathioprine and methylprednisolone in patients with severe myocarditis who did not improve left ventricular (LV) systolic function after 6 months of glucocorticoid (GC) therapy.Materials and methods. The study included 26 patients with chronic myocarditis, disease duration of more than 6 months and lack of efficacy of previous GC administration: functional class (FC) of HF remained at level II or higher, LV ejection fraction (EF) remained <40% at the time of inclusion in the study. All patients on the background of HF therapy according to modern standards were prescribed combined immunosuppressive therapy: azathioprine at a dose of 1 mg/kg of body weight for 6 months in combination with methylprednisolone at a dose of 0.25 mg/kg per day for 3 months with a gradual dose reduction of 1 mg per week until complete drug withdrawal 6 months after the start of treatment. Determination of the content of immunological biomarkers in the blood, cardiac magnetic resonance imaging (CMR) with intravenous contrast, transthoracic echocardiography and a 6-minute walk test were performed before the appointment of combined immunosuppressive therapy and after 6 months of treatment.Results. Before the appointment of combined immunosuppressive therapy, the average number of LV segments in which signs of inflammation were determined in the form of early contrast and/or T2 signal intensity enhancement was 7.25±0.36 segments, and the number of segments with fibrotic myocardial damage was 5.81±0.32 on average. After 6 months, inflammatory changes were detected only in 2.20±0.17 LV segments, while the volume of fibrotic LV damage did not significantly change compared to the initial examination. When analyzing echocardiography data after 6 months of observation, a significant decrease in the LV end-diastolic volume index by 15.6% (p<0.05) and an increase in LV EF by 16.7% (p<0.05) were found. Also, after 6 months of observation, a significant decrease in the content of systemic inflammation markers was detected: the level of ferritin decreased by 41.5% (p<0.01), C-reactive protein – by 34.2% (p<0.01), the content of interleukin-6 and tumor necrosis factor α decreased by 93.8% and 33.3%, respectively (p<0.01), and the content of troponin I decreased 3 times compared to the baseline level before the appointment of azathioprine. According to the results of the 6-minute test, before the appointment of azathioprine, patients with FC III HF predominated, only a third had FC II, and 20% – FC IV. After 6 months of treatment, more than half of the studied patients had FC II HF, every fourth – FC I, and FC IV was not diagnosed in any patient.Conclusions. In patients with severe myocarditis, combined immunosuppressive therapy with azathioprine and glucocorticoids for 6 months was accompanied by a decrease in dilatation and improving the contractility of the left ventricle, improving the functional class of heart failure, reducing the number of myocardial segments affected by inflammatory changes as well as reducing the content of systemic inflammation markers.
- 24 February 2025
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 20 (1) , 1-16
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
Introduction Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disorder caused by glucocorticoid (GC) use. It is one of the leading causes of secondary osteoporosis, increasing the risk of low-energy fractures, disability, and mortality. Although limited studies on GIOP epidemiology and treatment have been conducted in Ukraine, there were no national guidelines for its management. The aim was to create national guideline for the GIOP diagnosis, prevention, and treatment based on a comprehensive review of modern literature to enhance awareness within Ukraine’s medical community, improve disease management, and reduce its socio-economic impact. Materials and methods An Expert Group comprising 18 leading Ukrainian scientists from various fields was created for guideline development. A review of modern literature on GIOP epidemiology, risk factors, diagnosis, prevention, treatment, and monitoring was conducted. Evidence synthesis followed the GRADE methodology, and the quality of recommendations was critically evaluated using the AGREE II tool. Results The guideline comprises 12 statements covering GIOP screening, diagnosis, prevention, and treatment. We highlight the need to raise awareness among healthcare providers and patients about the potential effects of GC therapy. Also, we outline approaches to clinical assessment of osteoporotic fracture risk in GC users and detail diagnostic and therapeutic methods currently available in Ukraine for managing GIOP. Conclusion The first Ukrainian national GIOP guideline is critical for healthcare providers across specialities. Endorsed by the Board of the Ukrainian Association of Osteoporosis, it is recommended for use in routine clinical practice to enhance patient outcomes and mitigate the disease’s impact.
- 24 February 2025
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 20 (1) , 1-16
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
Introduction Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disorder caused by glucocorticoid (GC) use. It is one of the leading causes of secondary osteoporosis, increasing the risk of low-energy fractures, disability, and mortality. Although limited studies on GIOP epidemiology and treatment have been conducted in Ukraine, there were no national guidelines for its management. The aim was to create national guideline for the GIOP diagnosis, prevention, and treatment based on a comprehensive review of modern literature to enhance awareness within Ukraine’s medical community, improve disease management, and reduce its socio-economic impact. Materials and methods An Expert Group comprising 18 leading Ukrainian scientists from various fields was created for guideline development. A review of modern literature on GIOP epidemiology, risk factors, diagnosis, prevention, treatment, and monitoring was conducted. Evidence synthesis followed the GRADE methodology, and the quality of recommendations was critically evaluated using the AGREE II tool. Results The guideline comprises 12 statements covering GIOP screening, diagnosis, prevention, and treatment. We highlight the need to raise awareness among healthcare providers and patients about the potential effects of GC therapy. Also, we outline approaches to clinical assessment of osteoporotic fracture risk in GC users and detail diagnostic and therapeutic methods currently available in Ukraine for managing GIOP. Conclusion The first Ukrainian national GIOP guideline is critical for healthcare providers across specialities. Endorsed by the Board of the Ukrainian Association of Osteoporosis, it is recommended for use in routine clinical practice to enhance patient outcomes and mitigate the disease’s impact.
- Open Access
- 27 December 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (6) , 7-13
Results of one-year follow-up of patients with severe myocarditis associated with COVID-19 on glucocorticoid therapy
The aim of the study – to investigate the effectiveness and safety of glucocorticoid therapy in patients with severe myocarditis associated with COVID-19.Materials and methods. The results are based on data obtained from 72 patients with severe acute myocarditis (AM) and heart failure (HF) with reduced left ventricular ejection fraction (LVEF ≤ 40 %). Patients were divided into two groups: the group 1 included 34 patients with AM, who had a documented history of coronavirus disease ≤ 3 months before the onset of clinical symptoms of AM; the group 2 consisted of 38 patients with AM, who had no history of coronavirus disease. All patients received optimal therapy for heart failure during all period of follow-up and immunosuppressive therapy with glucocorticoids (GKs) within first 6 months from the onset of AM. Patients underwent for echocardiography with speckle tracking and cardiac magnetic resonance (CMR). The studies were conducted three times: in the first month from the onset of clinical symptoms of myocarditis, after 6 months, and after 12 months of observation.Results and discussion. After 6 months of follow-up, improvements in the structural and functional state of the heart were observed in both groups, with group 1 showing greater increases in LVEF and LGSS by 13.1 % and 22.2 %, respectively (p<0.05). Additionally, group 1 exhibited a reduction in the number of LV segments affected by inflammatory changes and the total number of damaged segments by 28.4 % and 18.3 %, respectively, compared to group 2 (p<0.05–0.001). After 12 months results of CMR demonstrated significantly less myocardial damage in group 1 compared to group 2: the total number of LV segments affected by inflammation and/or fibrosis was 39.0 % lower (p<0.001). The most common complications of GKs therapy after 6 months were obesity (13.88 %) and leukocytosis (12.50 %), while hypokalemia occurred in 6.94 % of cases. Complications such as arterial hypertension, hyperglycemia, functional hypercortisolism, and myalgia were recorded in 4.16 % of cases. After 12 months, a significant reduction or complete resolution of GC-associated complications was observed in most patients: only 7 cases (9.72 %) of pathology associated with GC therapy were recorded.Conclusions. In patients with acute severe myocarditis with a history of coronavirus disease, glucocorticoid therapy demonstrated greater efficacy in improving the structural and functional state of the heart after 6 months of follow-up compared to patients without a history of COVID-19. The use of glucocorticoids in patients with severe myocarditis was associated with the development of complications in more than a half of patients within the first 6 months of follow-up, while after 12 months, there was a significant reduction in their frequency or their complete regression. During the 12-month observation period, none of the patients developed diseases or pathological conditions associated with glucocorticoid use that required inpatient treatment.
- 27 December 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (6) , 7-13
Open AccessResults of one-year follow-up of patients with severe myocarditis associated with COVID-19 on glucocorticoid therapy
The aim of the study – to investigate the effectiveness and safety of glucocorticoid therapy in patients with severe myocarditis associated with COVID-19.Materials and methods. The results are based on data obtained from 72 patients with severe acute myocarditis (AM) and heart failure (HF) with reduced left ventricular ejection fraction (LVEF ≤ 40 %). Patients were divided into two groups: the group 1 included 34 patients with AM, who had a documented history of coronavirus disease ≤ 3 months before the onset of clinical symptoms of AM; the group 2 consisted of 38 patients with AM, who had no history of coronavirus disease. All patients received optimal therapy for heart failure during all period of follow-up and immunosuppressive therapy with glucocorticoids (GKs) within first 6 months from the onset of AM. Patients underwent for echocardiography with speckle tracking and cardiac magnetic resonance (CMR). The studies were conducted three times: in the first month from the onset of clinical symptoms of myocarditis, after 6 months, and after 12 months of observation.Results and discussion. After 6 months of follow-up, improvements in the structural and functional state of the heart were observed in both groups, with group 1 showing greater increases in LVEF and LGSS by 13.1 % and 22.2 %, respectively (p<0.05). Additionally, group 1 exhibited a reduction in the number of LV segments affected by inflammatory changes and the total number of damaged segments by 28.4 % and 18.3 %, respectively, compared to group 2 (p<0.05–0.001). After 12 months results of CMR demonstrated significantly less myocardial damage in group 1 compared to group 2: the total number of LV segments affected by inflammation and/or fibrosis was 39.0 % lower (p<0.001). The most common complications of GKs therapy after 6 months were obesity (13.88 %) and leukocytosis (12.50 %), while hypokalemia occurred in 6.94 % of cases. Complications such as arterial hypertension, hyperglycemia, functional hypercortisolism, and myalgia were recorded in 4.16 % of cases. After 12 months, a significant reduction or complete resolution of GC-associated complications was observed in most patients: only 7 cases (9.72 %) of pathology associated with GC therapy were recorded.Conclusions. In patients with acute severe myocarditis with a history of coronavirus disease, glucocorticoid therapy demonstrated greater efficacy in improving the structural and functional state of the heart after 6 months of follow-up compared to patients without a history of COVID-19. The use of glucocorticoids in patients with severe myocarditis was associated with the development of complications in more than a half of patients within the first 6 months of follow-up, while after 12 months, there was a significant reduction in their frequency or their complete regression. During the 12-month observation period, none of the patients developed diseases or pathological conditions associated with glucocorticoid use that required inpatient treatment.
- Open Access
- 8 September 2024
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 14 (3) , 107-132
Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis
Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few studies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its management until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.
- 8 September 2024
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 14 (3) , 107-132
Open AccessUkrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis
Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few studies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its management until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.
- Open Access
- 31 August 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (4) , 53−60
Визначення предикторів стійких порушень серцевого ритму у військовослужбовців із тяжким перебігом міокардиту
The aim – to study heart rhythm and conduction disturbances in different localization and distribution of myocardial lesions in combatants with severe myocarditis based on the results of a 6-month follow-up.Materials and methods. 46 male military personnel with a severe course of acute myocarditis (AM) with a reduced ejection fraction (EF) of the left ventricle (LV) (≤ 40 %) with an average age of (35,1±2,4) years were examined. Examinations were carried out in the 1st month after the onset of symptoms of myocarditis and after 6 months of observation. The diagnosis of myocarditis and the severe course of the disease were established on the basis of the Recommendations for the diagnosis and treatment of myocarditis of the All-Ukrainian Association of Cardiologists of Ukraine. All patients underwent for 24-hour ECG monitoring with analysis of the frequency and spectrum of rhythm and conduction disturbances and cardiac magnetic resonance (CMR) imaging with contrast analysis of the topography of the lesion and counting the number of LV segments affected by inflammatory changes and LV segments with the presence of late gadolinium enhancement (LGE).Results and discussion. When comparing the results of heart MRI with the data of daily ECG monitoring, a clear association of the presence of frequent ventricular extrasystoles (VE) and paroxysms of non-sustained ventricular tachycardia (NSVT) with the localization of LGE in the interventricular septum (IS) was established – among patients with LGE lesions at the onset of AM more than in a third (37.0 %) had frequent VE, and NSVT paroxysms, which increase the risk of developing life-threatening ventricular arrhythmias, were detected in 25,9 % of cases. After 6 months of observation in the presence of LGE in the IS, the frequency of detection of frequent VE and NSVT paroxysms was also significantly higher compared to other localization of the lesion and amounted to 20,0 and 13,3 %, respectively. With the help of correlation analysis, an associative relationship was revealed between the presence of LGE in the IS and the presence of frequent VE and NSVT paroxysms in the debut of myocarditis – r=0.73 (р<0.01) and r=0.66 (р<0,01) respectively, and also after 6 months of observation – r=0.65 (р<0.01) and r=0.59 (р<0.05), respectively. According to the results of the multivariate regression analysis, predictors of frequent VE persistence after 6 months were: LVEF ≤30 %; LV end-diastolic volume index ≥105 ml/m2; presence of inflammatory changes in ≥5.0 LV segments; presence of LGE in ≥4.0 LV segments and its presence in the IS, determined in the 1st month from the onset of the disease. The predictors NSVT paroxysms persistence after 6 months were the same factors with the exception of LV EF, and, according to the value of the β coefficient (β=1.302; p<0.001), the most significant contribution was the presence of LGE in the IS.Conclusions. In combatants with severe myocarditis, the presence of late gadolinium enhancement in the interventricular septum is an additional risk factor for the persistence of frequent ventricular extrasystoles and paroxysms of non-sustained ventricular tachycardia during 6 months, while the presence of late gadolinium enhancement in the posterior and lateral walls of the left ventricle has no reliable relationship with the presence of rhythm and conduction disorders. On the basis of multivariate regression analysis, predictors of frequent ventricular extrasystoles and paroxysms of non-sustained ventricular tachycardia persistence were established in combatants with myocarditis.
- 31 August 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (4) , 53−60
Open AccessВизначення предикторів стійких порушень серцевого ритму у військовослужбовців із тяжким перебігом міокардиту
The aim – to study heart rhythm and conduction disturbances in different localization and distribution of myocardial lesions in combatants with severe myocarditis based on the results of a 6-month follow-up.Materials and methods. 46 male military personnel with a severe course of acute myocarditis (AM) with a reduced ejection fraction (EF) of the left ventricle (LV) (≤ 40 %) with an average age of (35,1±2,4) years were examined. Examinations were carried out in the 1st month after the onset of symptoms of myocarditis and after 6 months of observation. The diagnosis of myocarditis and the severe course of the disease were established on the basis of the Recommendations for the diagnosis and treatment of myocarditis of the All-Ukrainian Association of Cardiologists of Ukraine. All patients underwent for 24-hour ECG monitoring with analysis of the frequency and spectrum of rhythm and conduction disturbances and cardiac magnetic resonance (CMR) imaging with contrast analysis of the topography of the lesion and counting the number of LV segments affected by inflammatory changes and LV segments with the presence of late gadolinium enhancement (LGE).Results and discussion. When comparing the results of heart MRI with the data of daily ECG monitoring, a clear association of the presence of frequent ventricular extrasystoles (VE) and paroxysms of non-sustained ventricular tachycardia (NSVT) with the localization of LGE in the interventricular septum (IS) was established – among patients with LGE lesions at the onset of AM more than in a third (37.0 %) had frequent VE, and NSVT paroxysms, which increase the risk of developing life-threatening ventricular arrhythmias, were detected in 25,9 % of cases. After 6 months of observation in the presence of LGE in the IS, the frequency of detection of frequent VE and NSVT paroxysms was also significantly higher compared to other localization of the lesion and amounted to 20,0 and 13,3 %, respectively. With the help of correlation analysis, an associative relationship was revealed between the presence of LGE in the IS and the presence of frequent VE and NSVT paroxysms in the debut of myocarditis – r=0.73 (р<0.01) and r=0.66 (р<0,01) respectively, and also after 6 months of observation – r=0.65 (р<0.01) and r=0.59 (р<0.05), respectively. According to the results of the multivariate regression analysis, predictors of frequent VE persistence after 6 months were: LVEF ≤30 %; LV end-diastolic volume index ≥105 ml/m2; presence of inflammatory changes in ≥5.0 LV segments; presence of LGE in ≥4.0 LV segments and its presence in the IS, determined in the 1st month from the onset of the disease. The predictors NSVT paroxysms persistence after 6 months were the same factors with the exception of LV EF, and, according to the value of the β coefficient (β=1.302; p<0.001), the most significant contribution was the presence of LGE in the IS.Conclusions. In combatants with severe myocarditis, the presence of late gadolinium enhancement in the interventricular septum is an additional risk factor for the persistence of frequent ventricular extrasystoles and paroxysms of non-sustained ventricular tachycardia during 6 months, while the presence of late gadolinium enhancement in the posterior and lateral walls of the left ventricle has no reliable relationship with the presence of rhythm and conduction disorders. On the basis of multivariate regression analysis, predictors of frequent ventricular extrasystoles and paroxysms of non-sustained ventricular tachycardia persistence were established in combatants with myocarditis.
- Open Access
- 1 May 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (2) , 22-40
Сhoice of RAAS blocker in the treatment of heart failure in acute myocarditis
The aim – to evaluate the effectiveness of sacubitril/valsartan and enalapril in heart failure treatment in patients with acute severe myocarditis with reduced left ventricular ejection fraction based on dynamic analysis of the heart structural and functional changes.Materials and methods. The study is based on the results of examinations of 90 patients with a severe course of acute myocarditis (AM) with reduced ejection fraction (EF) of the left ventricle (LV) – ≤40 %. The patients were divided into two groups: the 1st group included 48 patients who were treated with an angiotensin-converting enzyme (ACE) inhibitor – enalapril as part of heart failure (HF) therapy; the 2nd group included 42 patients with AM who received the sacubitril/valsartan combination instead of enalapril in the complex therapy of HF. All patients underwent a 6-minute walk test, echocardiography (EchoCG) with the speckle-tracking method, and cardiac magnetic resonance imaging (CMR). Examinations were carried out three times: in the 1st month from the onset of AM symptoms before the appointment of drug therapy, after 6 and 12 months of observation. Part of the patients from the 1st group, namely 25 patients (52.1 %) in whom the use of ACE inhibitors proved to be ineffective after six months, was transferred to the combination of sacubitril/valsartan (group 1A).Results and discussion. After six months of treatment, compared to the 1st group, the patients of the 2nd group were distinguished by better indicators of the structural and functional state of the heart, which characterise the contractility and volume of the LV – the values of LV EF and LV longitudinal global systolic strain (LGSS) were higher by 13,7 and 26.2 % respectively, LV end-diastolic volume index (EDVi) was 13.2% lower, as well as a 21.7 % lower number of LV segments in which delayed contrast was detected on cardiac MRI. After six months of taking the sacubitril/valsartan combination in 1A group patients, an improvement in the structural and functional state of the heart was also achieved: the values of LVEF and LGSS increased by 19.2 % and 27.9 %, respectively, and LV EDVi decreased by 19.0 %; the number of LV segments in which delayed enhancement was determined on cardiac MRI decreased by 30.7 %. With the help of regression analysis, it was established the presence of a set of factors that determine the priority of prescribing the sacubitril/valsartan combination as initial therapy in patients with severe myocarditis: presence of reduced LVEF – ≤40 %; pronounced decrease in longitudinal and circular global LV strain – ≤8.5 and ≤9.0 %, respectively; pronounced dilatation of the LV – EDVi ≥102 ml/m2; presence of III or higher HF functional class; presence of delayed enhancement in ≥ 5,0 LV segments according to cardiac MRI data.Conclusions. In patients with a severe course of myocarditis, the sacubitril/valsartan combination prescribed as initial therapy showed higher effectiveness compared to ACE inhibitors in terms of improving contractility and reducing LV dilatation, as well as improving the functional class of heart failure. A complex of factors has been established that prove the expediency of prescribing the sacubitril/valsartan combination as initial therapy for heart failure in patients with acute myocarditis.
- 1 May 2024
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 31 (2) , 22-40
Open AccessСhoice of RAAS blocker in the treatment of heart failure in acute myocarditis
The aim – to evaluate the effectiveness of sacubitril/valsartan and enalapril in heart failure treatment in patients with acute severe myocarditis with reduced left ventricular ejection fraction based on dynamic analysis of the heart structural and functional changes.Materials and methods. The study is based on the results of examinations of 90 patients with a severe course of acute myocarditis (AM) with reduced ejection fraction (EF) of the left ventricle (LV) – ≤40 %. The patients were divided into two groups: the 1st group included 48 patients who were treated with an angiotensin-converting enzyme (ACE) inhibitor – enalapril as part of heart failure (HF) therapy; the 2nd group included 42 patients with AM who received the sacubitril/valsartan combination instead of enalapril in the complex therapy of HF. All patients underwent a 6-minute walk test, echocardiography (EchoCG) with the speckle-tracking method, and cardiac magnetic resonance imaging (CMR). Examinations were carried out three times: in the 1st month from the onset of AM symptoms before the appointment of drug therapy, after 6 and 12 months of observation. Part of the patients from the 1st group, namely 25 patients (52.1 %) in whom the use of ACE inhibitors proved to be ineffective after six months, was transferred to the combination of sacubitril/valsartan (group 1A).Results and discussion. After six months of treatment, compared to the 1st group, the patients of the 2nd group were distinguished by better indicators of the structural and functional state of the heart, which characterise the contractility and volume of the LV – the values of LV EF and LV longitudinal global systolic strain (LGSS) were higher by 13,7 and 26.2 % respectively, LV end-diastolic volume index (EDVi) was 13.2% lower, as well as a 21.7 % lower number of LV segments in which delayed contrast was detected on cardiac MRI. After six months of taking the sacubitril/valsartan combination in 1A group patients, an improvement in the structural and functional state of the heart was also achieved: the values of LVEF and LGSS increased by 19.2 % and 27.9 %, respectively, and LV EDVi decreased by 19.0 %; the number of LV segments in which delayed enhancement was determined on cardiac MRI decreased by 30.7 %. With the help of regression analysis, it was established the presence of a set of factors that determine the priority of prescribing the sacubitril/valsartan combination as initial therapy in patients with severe myocarditis: presence of reduced LVEF – ≤40 %; pronounced decrease in longitudinal and circular global LV strain – ≤8.5 and ≤9.0 %, respectively; pronounced dilatation of the LV – EDVi ≥102 ml/m2; presence of III or higher HF functional class; presence of delayed enhancement in ≥ 5,0 LV segments according to cardiac MRI data.Conclusions. In patients with a severe course of myocarditis, the sacubitril/valsartan combination prescribed as initial therapy showed higher effectiveness compared to ACE inhibitors in terms of improving contractility and reducing LV dilatation, as well as improving the functional class of heart failure. A complex of factors has been established that prove the expediency of prescribing the sacubitril/valsartan combination as initial therapy for heart failure in patients with acute myocarditis.
- Open Access
- 1 April 2024
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 29 (1) , 59-66
Dynamics of heart rhythm disorders in combatants with acute myocarditis during a 6-month follow-up
The main factors of an unfavorable prognosis, are life-threatening heart rhythm disorders which determine the severity of the clinical course of myocarditis, in addition to impaired contractility and dilatation of the left ventricle (LV). The aim of the study was to assess the frequency and nature of arrhythmias and establish predictors of their long-term persistence, assess the severity of anxiety and depression, changes in heart rate variability in combatants on the background of changes in the structural and functional state of the left ventricle during a 6-month follow-up. The study included 52 male servicemen (combatants) with acute myocarditis (AM) with an average age of 33.4±2.5 years. All patients were assessed by Questionnaire according to the Hospital Anxiety and Depression Scale (HADS) and underwent 24 hour ECG monitoring, transthoracic echocardiography and cardiac magnetic resonance (CMR) with late enhancement using gadovist. At the onset of AM frequent supraventricular (30.7% of cases) and frequent ventricular (42.3% of cases) extrasystolic arrhythmia, as well as paroxysms of non-sustained ventricular tachycardia (26.9% of cases) on the background of heart rhythm variability disorders were recorded. After 6 months, there was an improvement in the structural and functional state of the heart, which was characterized by a decrease in dilatation and an improvement of LV systolic function, a decrease in the volume of the inflammatory lesion and the total number of affected LV segments revealed on cardiac MRI, which was associated with a decrease in the number of ventricular rhythm disorders and reduction of clinical manifestations of anxiety according to the HADS scale. The obtained data indicate that the persistence of supraventricular rhythm disorders is associated with the long-term presence of anxiety and low values of standard deviation of RR intervals (SDNN) and root mean square of successive differences between normal heartbeats (RMSSD). Also predictors of persistence of non-sustained ventricular tachycardia paroxysms were established – SDNN value ≤80.0 ms, LV end-diastolic volume index ≥95 ml/m2, total number of affected LV segments ≥6 segments, presence of delayed contrasting in ≥3 LV segments, presence of ≥12 points on the HADS scale and predictors of atrial fibrillation – SDNN value ≤80.0 ms, RMSSD value ≤12.0 ms, total number of affected segments of LV≥6 seg. and ≥12 points on the HADS anxiety scale, determined at the onset of AM.
- 1 April 2024
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 29 (1) , 59-66
Open AccessDynamics of heart rhythm disorders in combatants with acute myocarditis during a 6-month follow-up
The main factors of an unfavorable prognosis, are life-threatening heart rhythm disorders which determine the severity of the clinical course of myocarditis, in addition to impaired contractility and dilatation of the left ventricle (LV). The aim of the study was to assess the frequency and nature of arrhythmias and establish predictors of their long-term persistence, assess the severity of anxiety and depression, changes in heart rate variability in combatants on the background of changes in the structural and functional state of the left ventricle during a 6-month follow-up. The study included 52 male servicemen (combatants) with acute myocarditis (AM) with an average age of 33.4±2.5 years. All patients were assessed by Questionnaire according to the Hospital Anxiety and Depression Scale (HADS) and underwent 24 hour ECG monitoring, transthoracic echocardiography and cardiac magnetic resonance (CMR) with late enhancement using gadovist. At the onset of AM frequent supraventricular (30.7% of cases) and frequent ventricular (42.3% of cases) extrasystolic arrhythmia, as well as paroxysms of non-sustained ventricular tachycardia (26.9% of cases) on the background of heart rhythm variability disorders were recorded. After 6 months, there was an improvement in the structural and functional state of the heart, which was characterized by a decrease in dilatation and an improvement of LV systolic function, a decrease in the volume of the inflammatory lesion and the total number of affected LV segments revealed on cardiac MRI, which was associated with a decrease in the number of ventricular rhythm disorders and reduction of clinical manifestations of anxiety according to the HADS scale. The obtained data indicate that the persistence of supraventricular rhythm disorders is associated with the long-term presence of anxiety and low values of standard deviation of RR intervals (SDNN) and root mean square of successive differences between normal heartbeats (RMSSD). Also predictors of persistence of non-sustained ventricular tachycardia paroxysms were established – SDNN value ≤80.0 ms, LV end-diastolic volume index ≥95 ml/m2, total number of affected LV segments ≥6 segments, presence of delayed contrasting in ≥3 LV segments, presence of ≥12 points on the HADS scale and predictors of atrial fibrillation – SDNN value ≤80.0 ms, RMSSD value ≤12.0 ms, total number of affected segments of LV≥6 seg. and ≥12 points on the HADS anxiety scale, determined at the onset of AM.
- Open Access
- 27 December 2023
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 30 (5-6) , 51-57
Роль спекл-трекінг ехокардіографії в оцінці геометрії скорочення серця у військовослужбовців із гострим міокардитом
The aim – to evaluate the geometry of heart contraction based on speckle-tracking echocardiography data in combatants with acute myocarditis with reduced and mildly reduced left ventricular ejection fraction.Materials and methods. 53 male combatants with acute myocarditis (AM) were examined, who were divided into 2 groups: 1st group – 30 patients with a reduced ejection fraction (EF) of the left ventricle (LV) ≤ 40 %; 2nd group – 23 patients with mildly reduced LVEF 41–49 %. The diagnosis of AM was established on the basis of the recommendations for the diagnosis and treatment of myocarditis of the All-Ukrainian Association of Cardiologists of Ukraine. All patients underwent echocardiography (EchoCG) with speckle tracking (ST) and cardiac magnetic resonance (CMR) imaging with contrast.Results and discussion. Patients of the 1st group, compared to the 2nd, were characterized by more pronounced manifestations of dilatation and more significant violation of the LV contractile function, which was evidenced by a 13.6 % higher value of the LV end-diastolic volume and a 25.4 % smaller value of the LVEF. When evaluating ST echocardiographic indicators, the value of the longitudinal global systolic strain (LGSS) of the LV in the 1st group was 43.1 % lower, its velocity by 19.2 %, and the circular systolic deformation by 20.9 % in comparison with those in the 2nd group. In addition, in the 1st group, in comparison with the 2nd, the value of the indicator of systolic deformation of the left atrium (SDLA) was almost twice smaller. According to the results of CMR, in the 1st group compared to the 2nd, a larger number of segments with the presence of delayed enhancement was determined, which indicated a larger volume of fibrotic/necrotic lesions of the LV. According to the results of the correlation analysis in the 1st group, strong reverse relationships were established between the presence of delayed contrast in ≥ 4 segments of the LV and LGSS (r=–0.76; p<0.01), its speed and (r=–0.71; p<0.02) and SDLA (r=–0.52; p<0.05).Conclusions. Patients with acute myocarditis with a reduced left ventricular ejection fraction compared to patients with a mildly reduced ejection fraction were characterized by a greater violation of the geometry of the contraction of the left ventricle, which was observed on the background of a larger volume of fibrotic/necrotic lesions. With the help of correlation analysis, in combatants with acute myocarditis, a relationship was established between the presence of delayed enhancement in ≥ 4 segments of the left ventricle and a decrease in indicators of longitudinal systolic deformation and its speed, as well as an indicator of systolic deformation of the left atrium.
- 27 December 2023
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 30 (5-6) , 51-57
Open AccessРоль спекл-трекінг ехокардіографії в оцінці геометрії скорочення серця у військовослужбовців із гострим міокардитом
The aim – to evaluate the geometry of heart contraction based on speckle-tracking echocardiography data in combatants with acute myocarditis with reduced and mildly reduced left ventricular ejection fraction.Materials and methods. 53 male combatants with acute myocarditis (AM) were examined, who were divided into 2 groups: 1st group – 30 patients with a reduced ejection fraction (EF) of the left ventricle (LV) ≤ 40 %; 2nd group – 23 patients with mildly reduced LVEF 41–49 %. The diagnosis of AM was established on the basis of the recommendations for the diagnosis and treatment of myocarditis of the All-Ukrainian Association of Cardiologists of Ukraine. All patients underwent echocardiography (EchoCG) with speckle tracking (ST) and cardiac magnetic resonance (CMR) imaging with contrast.Results and discussion. Patients of the 1st group, compared to the 2nd, were characterized by more pronounced manifestations of dilatation and more significant violation of the LV contractile function, which was evidenced by a 13.6 % higher value of the LV end-diastolic volume and a 25.4 % smaller value of the LVEF. When evaluating ST echocardiographic indicators, the value of the longitudinal global systolic strain (LGSS) of the LV in the 1st group was 43.1 % lower, its velocity by 19.2 %, and the circular systolic deformation by 20.9 % in comparison with those in the 2nd group. In addition, in the 1st group, in comparison with the 2nd, the value of the indicator of systolic deformation of the left atrium (SDLA) was almost twice smaller. According to the results of CMR, in the 1st group compared to the 2nd, a larger number of segments with the presence of delayed enhancement was determined, which indicated a larger volume of fibrotic/necrotic lesions of the LV. According to the results of the correlation analysis in the 1st group, strong reverse relationships were established between the presence of delayed contrast in ≥ 4 segments of the LV and LGSS (r=–0.76; p<0.01), its speed and (r=–0.71; p<0.02) and SDLA (r=–0.52; p<0.05).Conclusions. Patients with acute myocarditis with a reduced left ventricular ejection fraction compared to patients with a mildly reduced ejection fraction were characterized by a greater violation of the geometry of the contraction of the left ventricle, which was observed on the background of a larger volume of fibrotic/necrotic lesions. With the help of correlation analysis, in combatants with acute myocarditis, a relationship was established between the presence of delayed enhancement in ≥ 4 segments of the left ventricle and a decrease in indicators of longitudinal systolic deformation and its speed, as well as an indicator of systolic deformation of the left atrium.
- Open Access
- 27 September 2023
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 13 (3) , 128-154
Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis
Background. Postmenopausal osteoporosis (PMO), which is developed due the estrogen defi ciency in women after menopause, is the most common type of systemic osteoporosis. The latest Ukrainian recommendation for its management requires revision due to new data from high-quality research performed in recent years. The purpose was to develop a guideline on the diagnosis, prevention, and treatment of PMO based on an analytical analysis of modern literary sources in order to improve the awareness of the medical community of Ukraine. Methodology. To develop the guideline, an expert group of 13 leading Ukrainian scientists of various specialties was created who conducted a tho rough review of modern literature on this topic, assessed the level of existing evidence using the GRADE system, proposed and voted on 15 recommendations of the guideline. Results. The guideline contains chapters on diagnosis and diff erential diagnosis of PMO, assessment of the osteoporotic fracture risk, the role of bone turnover markers in the management of PMO, and modern strategies of antiosteoporotic treatment. Conclusions. The Ukrainian guideline on the diagnosis, prevention, and treatment of PMO, which contains 15 main recommendations, created on the basis of a tho rough analysis and synthesis of modern literature data, is an important tool for the management of PMO and is recommended by Ukrainian Association of Osteoporosis for use in Ukrainian me dical community.
- 27 September 2023
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 13 (3) , 128-154
Open AccessGuideline for diagnostic, prevention and treatment of postmenopausal osteoporosis
Background. Postmenopausal osteoporosis (PMO), which is developed due the estrogen defi ciency in women after menopause, is the most common type of systemic osteoporosis. The latest Ukrainian recommendation for its management requires revision due to new data from high-quality research performed in recent years. The purpose was to develop a guideline on the diagnosis, prevention, and treatment of PMO based on an analytical analysis of modern literary sources in order to improve the awareness of the medical community of Ukraine. Methodology. To develop the guideline, an expert group of 13 leading Ukrainian scientists of various specialties was created who conducted a tho rough review of modern literature on this topic, assessed the level of existing evidence using the GRADE system, proposed and voted on 15 recommendations of the guideline. Results. The guideline contains chapters on diagnosis and diff erential diagnosis of PMO, assessment of the osteoporotic fracture risk, the role of bone turnover markers in the management of PMO, and modern strategies of antiosteoporotic treatment. Conclusions. The Ukrainian guideline on the diagnosis, prevention, and treatment of PMO, which contains 15 main recommendations, created on the basis of a tho rough analysis and synthesis of modern literature data, is an important tool for the management of PMO and is recommended by Ukrainian Association of Osteoporosis for use in Ukrainian me dical community.
- Open Access
- 30 June 2023
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 13 (2) , 60-76
Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement
Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommended increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we recommend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.
- 30 June 2023
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 13 (2) , 60-76
Open AccessDiagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement
Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommended increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we recommend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.